Frankfurt
06.02.26 | 15:25
17,700 Euro
+0,57 % +0,100
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 17,500 | 18,200 | 10:22 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.01. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| 17.12.25 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 9 | GlobeNewswire (USA) | ||
| 15.12.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.12.25 | Nanobiotix S.A.: NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris | 239 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| 01.12.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.11.25 | Leerink Partners raises Nanobiotix stock price target to $26 on pipeline progress | 2 | Investing.com | ||
| 24.11.25 | Nanobiotix S.A. provides Q3 Operational and Financial Update | 1 | Seeking Alpha | ||
| 24.11.25 | Nanobiotix S.A.: Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook | 453 | GlobeNewswire (Europe) | Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty ("HCRx") of a non-dilutive royalty financing valued up to $71 millionProgress in the... ► Artikel lesen | |
| 24.11.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.11.25 | Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue | 1 | The Motley Fool | ||
| 14.11.25 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 13.11.25 | Nanobiotix S.A.: NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations | 4 | GlobeNewswire (USA) | ||
| 12.11.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.11.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 31.10.25 | Cash-strapped Nanobiotix finds fresh way to source cash from J&J-partnered cancer drug | 12 | FierceBiotech | ||
| 31.10.25 | Nanobiotix S.A.: NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth | 306 | GlobeNewswire (Europe) | $71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes... ► Artikel lesen | |
| 24.10.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| 24.10.25 | Nanobiotix S.A.: NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control | 387 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| 15.10.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 15.10.25 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 15,510 | -3,21 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,550 | -5,49 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 68,80 | +0,15 % | Halozyme Therapeutics: Die bessere Evotec? | Halozyme Therapeutics ist den meisten Anlegern hierzulande vermutlich durch den Übernahmeversuch Evotecs vorletztes Jahr bekannt. Eine Akquisition zu 11 € je Aktie scheiterte jedoch, da die Deutschen... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,636 | -1,24 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| GLOW LIFETECH | 0,025 | -12,28 % | Glow Lifetech Corp.: Glow Lifetech Announces Expansion into Manitoba Market and Portfolio Expansion in New Brunswick, Advancing National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - February 3, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the expansion of its MOD and .decimal... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 255,00 | 0,00 % | Biodesix, Inc.: Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays | LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Rich McAvoy as Chief Business Officer | Seasoned business and finance leader brings disciplined growth mindset to support Avid's next phase of expansion and client executionTUSTIN, Calif., Jan. 15, 2026 /PRNewswire/ -- Avid Bioservices... ► Artikel lesen | |
| BIOLINERX | 2,225 | -5,32 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,620 | -10,84 % | Minerva Neurosciences, Inc. - 8-K, Current Report | ||
| WHITEHAWK THERAPEUTICS | 2,220 | -5,93 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer | Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic
MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,080 | -100,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,290 | -3,73 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| GEOVAX LABS | 2,700 | +4,65 % | EQS-News: GeoVax Labs, Inc.: GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement | GeoVax, Inc. / Key word(s): Financial
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
08.01.2026 / 15:03 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| COCRYSTAL | 0,770 | -6,67 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis... ► Artikel lesen |
Das Unternehmen NANOBIOTIX SA ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,57 % bei einem Aktienkurs von 17,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.